Publications
NEO-TRA1: A CD25-Targeted De Novo non-Alpha Agonist of the IL-2 Receptor Selectively Expands Regulatory T Cells
ASH Annual Meeting, Oral Presentation, Publication # 684, December 2022
NL-201, a de novo engineered IL2/IL15 mimic, synergizes with radiation to generate potent antitumor immunity
AACR Annual Meeting, Abstract 2067, April 2022.
NL-201, a de novo agonist of IL-2 and IL-15 receptors, demonstrates antitumor activity in preclinical B cell lymphoma models
AACR Annual Meeting, Abstract #4227, April 2022.
NL-201, a de novo engineered IL2/IL15 mimic, synergizes with radiation to generate potent antitumor immunity
AACR Annual Meeting, Abstract 2067, April 2022.
A first-in-human Phase 1 study of NL-201 in patients with relapsed or refractory cancer
AACR Annual Meeting, Abstract CT250, April 2022
Antiviral NL-CVX1 efficiently blocks infection by SARS-CoV-2 viral variants of concern (VOC).
(Conference Track A1, Session [O-27]: Novel Microbial Agents) IDWeek 2021. September 29, 2021
The IL-2/IL-15 Mimetic NL-201 Prevents Myeloma Relapse after ASCT by Expanding Highly Cytolytic T Cells in the Bone Marrow that are Resistant to Exhaustion.
American Society of Hematology 63rd Annual Meeting. Abstract 1609. December 2021.
NL-201, a De Novo Agonist of IL-2 and IL-15 Receptors, Demonstrates Synergistic Antitumor Activity with Anti-PD-1 Checkpoint Inhibitor Therapy in a Preclinical Non-Hodgkin Lymphoma Model.
Huard et. al. Blood (2021) 138 (Supplement 1): 4560.
NL-201 Induces Inflammation in a ‘Cold’ Tumor Microenvironment through Upregulation of MHC-I, Expansion of the TCR Repertoire, and Potent Antitumor Activity when Combined with PD-1 Inhibition
Mortales et. Al, SITC 2021, Abstract #716, November 2021
Intratumoral Administration of NL-201, an Alpha-Independent IL-2/15 Receptor Agonist, Inhibits the Growth of Both Injected and Uninjected Tumors in Preclinical Models
Tatalick et. Al, SITC 2021, Abstract #898, November 2021
A First-in-Human Phase 1 Study of NL-201 in Patients with Relapsed or Refractory Cancer (Trials in Progress)
Ulge et. Al, SITC 2021, Abstract #509, November 2021
ICT01, an Anti-BTN3A Monoclonal Antibody, and NL-201, an Alpha-Independent IL-2/IL-15 Agonist, Combine to Elicit a Potent Anti-Tumor Response by Synergistically Stimulating g9d2 T Cell Activation and Proliferation
De Gassart et. Al, SITC 2021, Abstract #563, November 2021
Development of a Computationally Designed, Hyperstable Dual Inhibitor of the IL-2 and IL-15 Receptors: A Novel Therapeutic Candidate for Inflammatory Conditions
T. Linksy et. Al. Arthritis Rheumatology. 2021; 73 (suppl 10). November 8, 2021
Antiviral NL-CVX1 efficiently blocks infection by SARS-CoV-2 viral variants of concern (VOC).
(Conference Track A1, Session [O-27]: Novel Microbial Agents) IDWeek 2021. September 29, 2021
NL-201, a de novo IL-2/IL-15 agonist, demonstrates enhanced in vivo antitumor activity in combination with multiple cancer immunotherapies
Walkey et. Al, SITC 2020, Abstract #576, November 2020
View Poster
De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2
T. W. Linsky et. al. Science. 10.1126/science.abe0075 (2020)
Pre-clinical development of NL-201: A de novo α-independent IL-2/IL-15 agonist
Walkey et. Al, AACR Virtual Annual Meeting II, Abstract #4518, June 2020
View Poster
Access poster/presentation at AACR.org
Engineered variants of Neo-2/15 potently expand CAR-T cells and promote antitumor activity in lymphoma and solid tumor mouse models
Leung, et. Al, AACR Virtual Annual Meeting II, Abstract #222, June 2020
View Poster
Access poster/presentation at AACR.org
Conditionally active de novo IL-2 cytokine mimetics for targeted immunotherapy: de novo split technology
Quijano-Rubio et. Al., AACR Virtual Annual Meeting II, Abstract #1075, Jun/2020
Access presentation at AACR.org
De novo design of potent and selective mimics of IL-2 and IL-15
DA Silva et al. Nature. VOL 565, pages 186–191 (2019)
The advent of de novo proteins for cancer immunotherapy
Alfredo Quijano-Rubio, Umut Y. Ulge, Carl D. Walkey, Daniel-Adriano Silva. Current Opinion in Chemical Biology (in press) Available online 1 May 2020.